TMPRSS2 and prostate cancer: Lindquist and coworkers have analyzed the genomes of 24 AAM with aggressive prostate cancer with Gleason grades ≥7 and confirmed in these patients a low prevalence of TMPRSS2-ERG fusions (20%) and of PTEN deletions (8%) [315].